P/E RATIO

Without taking fundamentals into consideration we believe the stock is setting up for a nice move on earnings Final consideration will be made before close of trade today, if price reaction is good it will confirm our bullish belief.AVERAGE ANALYSTS PRICE TARGET $14AVERAGE ANALYSTS RECOMMENDATION HoldSHORT INTEREST 31%%COMPANY PROFILEis a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Makena,, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.